Clinical Trial Update: A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and Relapsed /Refractory Pediatric Acute Leukemia Patients [Phase 1]

View source ↗

Summary

A Phase Ia/Ib clinical trial update describes testing Revumenib in combination with cytarabine, daunorubicin, and gemtuzumab ozogamicin in frontline and relapse…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Daunorubicin (daunorubicin)
• Gemtuzumab ozogamicin (gemtuzumab ozogamicin)
• Revumenib (revumenib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Pediatric Acute Leukemia | Phase 1 | Status: NOT_YET_RECRUITING